Summary
The PARTNER trial now reports that TAVR was noninferior to surgical AVR, the current standard of care, in preventing mortality at 1 year in high-risk patients with symptomatic severe aortic stenosis (Cohort A).
- Cardiology Clinical Trials
- Interventional Techniques & Devices
- Valvular Disease
- © 2011 MD Conference Express
Tools
TAVR is Noninferior to Surgical AVR in High-Risk Patients with Aortic Stenosis: Results from the PARTNER Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.